Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 3, 2015, Pages 454-459

  Bejanyan, Nelli ^a   Weisdorf, Daniel J ^a   Logan, Brent R ^b   Wang, Hai Lin ^b   Devine, Steven M ^c   de Lima, Marcos ^d   Bunjes, Donald W ^e   Zhang, Mei Jie ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Acute myeloid leukemia; Allogeneic transplantation; Donor lymphocyte infusion; Relapse; Second transplantation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CHILD; CYTOGENETICS; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; AGE; ALLOGRAFT; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; INFANT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; NEWBORN; PRESCHOOL CHILD; RECURRENT DISEASE; REGISTER; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALLOGRAFTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84922925469     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.11.007     Document Type: Article

References (21)

1. Schmid C., Labopin M., Nagler A., et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012, 119:1599-1606.
2. Devillier R., Crocchiolo R., Etienne A., et al. Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma 2013, 54:1228-1234.
3. Savani B.N., Mielke S., Reddy N., et al. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009, 44:769-777.
4. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. JClin Oncol 2007, 25:4938-4945.
5. Thanarajasingam G., Kim H.T., Cutler C., et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:1713-1718.
6. van den Brink M.R., Porter D.L., Giralt S., et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant 2010, 16:S138-S145.
7. Bejanyan N., Oran B., Shanley R., et al. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. Bone Marrow Transplant 2014, 49:1029-1035.
8. Eapen M., Giralt S.A., Horowitz M.M., et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004, 34:721-727.
9. Arellano M.L., Langston A., Winton E., et al. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007, 13:116-123.
10. Loren A.W., Porter D.L. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008, 41:483-493.
11. Oran B., Giralt S., Couriel D., et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007, 21:2540-2544.
12. Levine J.E., Braun T., Penza S.L., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. JClin Oncol 2002, 20:405-412.
13. Lee J.H., Lee K.H., Kim S., et al. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. Leuk Res 2001, 25:305-312.
14. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
15. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
16. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
17. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009, 15:367-369.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
19. Kedmi M., Resnick I.B., Dray L., et al. Aretrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant 2009, 15:483-489.
20. Porter D.L., Alyea E.P., Antin J.H., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:1467-1503.
21. Bishop M.R., Alyea E.P., Cairo M.S., et al. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant 2011, 17:443-454.